Adjusting for differences in age and tumor size among departments, we found that HER2-targeted therapy strictly followed that of HER2 positivity, with only one oncology department outside of the overall CI and 3 out of 406 comparisons statistically significantly different (Figure 3B). Here, ERBB2 is linked to neoplasm.